Axonics Modulation Technologies Inc (AXNX) Stock
AXNX is no longer traded. Axonics Modulation Technologies was acquired by Boston Scientific (BSX) on November 15, 2024.
Each AXNX share was exchanged for $71.00 in cash. Prices on this page are historical; the last trade was November 14, 2024 at $70.98.
See Boston Scientific (BSX) stock →Axonics Modulation Technologies stock price history
AXNX final trading statistics
- Final close
- $70.98
- Final trading day
- Nov 14, 2024
- Market cap at delisting
- $3.63B
- Shares outstanding
- 51.11M
- Final 52-week range
- $55.09 – $71.05
- Avg. volume (final 3 mo.)
- 456,607
- All-time high (split-adj.)
- $78.66 · Sep 2021
- All-time low (split-adj.)
- $13.20 · Nov 2018
- Return since IPO
- +373.8%
- Beta
- 0.83
- Book value / share
- $13.00
- Price / book
- 5.46
Axonics Modulation Technologies annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $366.38M | -$6.1M | $0.18 |
| FY2022 | $273.70M | -$59.7M | -$1.30 |
| FY2021 | $180.29M | -$80.1M | -$1.77 |
| FY2020 | $111.53M | -$54.9M | -$1.50 |
| FY2019 | $13.82M | -$79.9M | -$2.79 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Axonics Modulation Technologies Inc
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation.
Axonics Modulation Technologies stock FAQ
What happened to Axonics Modulation Technologies stock?
Axonics Modulation Technologies was acquired by Boston Scientific (BSX) on November 15, 2024. Shareholders received $71.00 in cash for each share. AXNX stock stopped trading on the Nasdaq, with a final close of $70.98 on November 14, 2024.
What did Axonics Modulation Technologies shareholders receive?
Each AXNX share was converted into $71.00 in cash. The deal was valued at about $3.7 billion.
Is AXNX stock still trading?
No. AXNX was delisted from the Nasdaq on November 15, 2024 and no longer trades on a U.S. exchange.
What was the last price of AXNX stock?
AXNX closed at $70.98 on its final trading day, November 14, 2024, for a market value of about $3.63B.
What were Axonics Modulation Technologies's revenue and earnings in its last full fiscal year?
Axonics Modulation Technologies reported revenue of $366.38M and net income of -$6.1M in fiscal 2023, its last full year as a public company.
When did Axonics Modulation Technologies go public?
Axonics Modulation Technologies Inc stock began trading on October 31, 2018.